



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	BBI-093CP
-------	---	----	---	------------------------	-----------

Complete if Known

Application Number	BBI-093CP
Filing Date	March 24, 2000
First Named Inventor	Salfeld, Jochen G.
Art Unit	1647
Examiner Name	Hamud, Fozia M.
Attorney Docket Number	BBI-093CP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EH	G1	Jackson, J.J. et al. "In vitro maturation: improvement of a high affinity, neutralizing antibody against IL-18." <i>The Journal of Immunology</i> 154(7):3310-19 (1995).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Fozia M. Hamud</i>	Date Considered	07/07/04
-----------------------	-----------------------	--------------------	----------

SEP 24 2003
CANCELED
PATENT & TRADEMARK OFFICE

SEP 23 2003
PATENT & TRADEMARK OFFICE

Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO BBI-093CP	SERIAL NO. 09/534717
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Salfeld, Jochen et al.	
		FILING DATE March 24, 2000	RECEIVED OCT 9 2003 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FIGURE DATE IF APPROPRIATE
FH	F1	5,780,597	07/98	Gately et al.	530		
FH	F2	6,090,382	07/00	Salfeld et al.	424	133.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
FH	F3	WO 99/37682 A2	07/99	WO			
FH	F4	WO 02/12500 A2	02/02	WO			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

Examiner	<i>For Hand</i>	Date Considered	<i>07/07/09</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO BBI-093CP	SERIAL NO 09/534,717
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Jochen Salfeld et al.	GROUP 1648
		FILING DATE March 24, 2000	

U.S. PATENT DOCUMENTS

ENTRY NUMBER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILINGS DATE
FH A1	4,816,397	3/89	Boss et al.	435	68	
FH A2	5,658,754	8/97	Kawasaki	435	69.1	
FH A3	5,643,768	7/97	Kawasaki	435	91.21	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
FH A4	WO 9404679 A1	3/94	PCT			
FH A5	EP 0 659 766 A1	6/95	EPO			
FH A6	WO 9524918 A1	9/95	PCT			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

FH A7	Balashov KE, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):599-603
FH A8	Barbas CF 3rd, et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7978-82
FH A9	Berrebi D, et al. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am J Pathol. 1998 Mar;152(3):667-72
FH A10	Bird RE, et al. Single-chain antigen-binding proteins. Science. 1988 Oct 21;242(4877):423-6
FH A11	Brown PS Jr, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2663-7
FH A12	Bucht A, et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol. 1996 Mar;103(3):357-67
FH A13	Carter RW, et al. "Production and characterization of monoclonal antibodies to human interleukin-12," Hybridoma. 1997 Aug;16(4):363-9
FH A14	Clackson T, et al. Making antibody fragments using phage display libraries. Nature. 1991 Aug 15;352(6336):624-8
FH A15	Dall'Acqua W, et al. Antibody engineering. Curr Opin Struct Biol. 1998 Aug;8(4):443-50

Examiner	<i>Bon V. ...</i>	Date Considered	07/07/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Jochen Salfeld et al.

FILING DATE

March 24, 2000

GROUP

1646

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)


B1	Fais S, et al. Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res. 1994 Oct;14(5):235-8
B2	Fuchs P, et al. Targeting recombinant antibodies to the surface of Escherichia coli: fusion to a peptidoglycan associated lipoprotein. Biotechnology (N Y). 1991 Dec;9(12):1369-72
B3	Fuss IJ, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996 Aug 1;157(3):1261-70
B4	Gately MK, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521
B5	Garrard LJ, et al. F _{ab} assembly and enrichment in a monovalent phage display system. Biotechnology (N Y). 1991 Dec;9(12):1373-7
B6	Gram H, et al. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3576-80
B7	Griffiths AD, et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 1993 Feb;12(2):725-34
B8	Hanes J, et al. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A. 1997 May 13;94(10):4937-42
B9	Hawkins RE, et al. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992 Aug 5;226(3):889-96
B10	Hay BN, et al. Bacteriophage cloning and Escherichia coli expression of a human IgM Fab. Hum Antibodies Hybridomas. 1992 Apr;3(2):81-5
B11	Duchmann et al., Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 1996, 26:934-8 (Abstract)
B12	Hoogenboom HR, et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 1991 Aug 11;19(15):4133-7
B13	He M, et al. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 1997 Dec 15;25(24):5132-4
B14	Huse WD, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989 Dec 8;246(4935):1275-81

Examiner

Date Considered

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 509; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



John H. and

07/07/04

REV 7-88

BBI-093CP

09/534,717

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Jochen Salfeld et al.

FILING DATE

March 24, 2000

GROUP

1646

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

FH	C1	Huston JS, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. <i>Proc Natl Acad Sci U S A</i> . 1988 Aug;85(16):5879-83
FH	C2	Irving RA, et al. Affinity maturation of recombinant antibodies using E. coli mutator cells. <i>Immunotechnology</i> . 1996 Jun;2(2):127-43
FH	C3	Jungmans RP, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. <i>Cancer Res</i> . 1990 Mar 1;50(5):1495-502
FH	C4	Kabat EA, et al. Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains. <i>Ann N Y Acad Sci</i> . 1971 Dec 31;190:382-93
FH	C5	Kobayashi M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. <i>J Exp Med</i> . 1989 Sep 1;170(3):827-45
FH	C6	Ling P, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. <i>J Immunol</i> . 1995 Jan 1;154(1):116-27
FH	C7	McCafferty J, et al. Phage antibodies: filamentous phage displaying antibody variable domains. <i>Nature</i> . 1990 Dec 6;348(6301):552-4
FH	C8	Monteleone G, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. <i>Gastroenterology</i> . 1997 Apr;112(4):1169-78
FH	C9	Morita Y, et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. <i>Arthritis Rheum</i> . 1998 Feb;41(2):306-14
FH	C10	Neurath MF, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. <i>J Exp Med</i> . 1995 Nov 1;182(5):1281-90
FH	C11	Parronchi P, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. <i>Am J Pathol</i> . 1997 Mar;150(3):823-32
FH	C12	Pini A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. <i>J Biol Chem</i> . 1998 Aug 21;273(34):21769-76
FH	C13	Pini A, et al. "Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma," <i>J Immunol Methods</i> . 1997 Aug 7;206(1-2):171-82
FH	C14	Podlaski FJ, et al. Molecular characterization of interleukin 12. <i>Arch Biochem Biophys</i> . 1992 Apr;294(1):230-7

Examiner

Bona Hand

Date Considered

07/07/04

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O I P E

FEB 27 2002


PATENT & TRADEMARK

RECEIVED
MAR 03 2002
TECH CENTER 1400/2000

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. BBI-093CP	SERIAL NO. 09/534,717
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Jochen Salfeld et al.	GROUP 1646
		FILING DATE March 24, 2000	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

01	FEH	Seder RA, et al. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10188-92
02	FEH	Sharon J. Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4814-7
03	FEH	Taylor LD, et al. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 1992 Dec 11;20(23):6287-95
04	FEH	Turka LA, et al. Interleukin 12: a potential link between nerve cells and the immune response in inflammatory disorders. Mol Med. 1995 Sep;1(6):690-9
05	FEH	Windhagen A, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 1995 Dec 1;182(6):1985-96
06	FEH	Winter G, et al. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433-55
07	FEH	Hamid Q, et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996 Jul;98(1):225-31
08	FEH	Kabat, E.A., et al. <i>Sequences of Proteins of Immunological Interest, Fifth Edition</i> , U.S. Department of Health and Human Services, NIH Publication No. 91-3242, 1991 (Abstract) NTIS [online]. Retrieved from: Dialog Information Services, Palo, Alto, CA, USA. NTIS Accession No. PB 91-192898, Dialog Accession NO. 1606873.
Examiner	<i>Bona Hand</i>	Date Considered
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-093CP

09/534,717

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Jochen Salfeld et al.

FILING DATE

March 24, 2000

GROUP

1646

FEB 27 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
F4	E1	WO 97/15327	5/97					
F4	E2	WO 92/20791	11/92					
F4	E3	WO 92/01047	1/92					
F4	E4	WO 92/09690	7/92					

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

<div style="position: absolute; top: 10px; left: 10px; font-size: 2em; font-weight: bold;">FH</div>	ES	Kettleborough et al., Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 1991, 4:773-83 (Abstract)	
Examiner	<i>Paul Horn</i>		Date Considered <i>07/07/04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			